Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Titel:
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Auteur:
Smit, Egbert F. Garon, Edward B. Reck, Martin Cappuzzo, Federico Bidoli, Paolo Cohen, Roger B. Gao, Ling O’Brien, Lisa M. Lee, Pablo Zimmermann, Annamaria Ferry, David R. Melemed, Allen S. Pérol, Maurice